Predictive value of aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy

Clinical Cancer Research

Volumn 13, Issue 14, 2007, Pages 4083-4091

  Lassmann, Silke ^a   Shen, Yi ^a,c   Jütting, Uta ^b   Wiehle, Philipp ^a   Walch, Axel ^b   Gitsch, Gerald ^a   Hasenburg, Annette ^a   Werner, Martin ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; CARBOPLATIN; DOXORUBICIN; PACLITAXEL; TOPOTECAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CENTROMERE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; ENZYME REGULATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICRODISSECTION; MONOTHERAPY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 34547135182     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2775     Document Type: Article

References (46)

1. Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001;127:73-9.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006;107:1399-410.
4. Scott M, McCluggage WG. Current concepts in ovarian epithelial tumourigenesis: correlation between morphological and molecular data. Histol Histopathol 2006;21:81-92.
5. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
6. Tavassoli FA, Deville P, editors. WHO classification of tumours: tumours of the breast and female genital organs. Lyon: IARC Press; 2003.
7. du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16 Suppl 8:viii7-12.
8. Pfisterer J, Harter P, Canzler U, et al. AGO Ovarian Cancer Study Group (AGO-OVAR). The role of surgery in recurrent ovarian cancer. Int J Gynecol Cancer 2005;15 Suppl 3:195-8.
9. Pignata S, Pisano C, Di Maio M, et al. Medical treatment of resistant or recurrent epithelial ovarian cancer. Ann Oncol 2006;17 Suppl 7:vii49-50.
10. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-16.
11. Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol 1998;25:305-14.
12. Tanner MM, Grenman S, Koul A, et al. Frequent amplification of chromosomal region 20q12-13 in ovarian cancer. Clin Cancer Res 2000;6:1833-9.
13. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-93.
14. Marumoto T, Zhang D, Saya H. Aurora-A - a guardian of poles. Nat Rev Cancer 2005;5:42-50.
15. Giet R, Petretti C, Prigent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol 2005;15:241-50.
16. Tong T, Zhong Y, Kong J, et al. Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 2004;10:7304-10. Erratumin: Clin Cancer Res 2005;11:4635.
17. Li D, Zhu J, Firozi PF, Abbruzzese JL, et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003;9:991-7.
18. Sakakura C, Hagiwara A, Yasuoka R, et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 2001;84:824-31.
19. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052-65.
20. Sen S, Zhou H, Zhang RD, et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002;94:1320-9.
21. Miyoshi Y, Iwao K, Egawa C, Noguchi S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 2001;92:370-3.
22. GritskoTM, Coppola D, Paciga JE, et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 2003;9:1420-6.
23. Chung CM, Man C, Jin Y, et al. Amplification and overexpression of aurora kinaseA (AURKA) in immortalized human ovarian epithelial (HOSE) cells. Mol Carcinog 2005;43:165-74.
24. Hu W, Kavanagh JJ, Deaver M , et al. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumourigenic cell cultures derived from human ovarian cancer. Oncol Res 2005;15:49 -57.
25. Tanaka E, Hashimoto Y, Ito T, et al.The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin Cancer Res 2005;11:1827-34.
26. Reiter R, Gais P, Jutting U, et al. Aurora kinase a messenger RNA overexpression is correlated with tumour progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12:5136-41.
27. Hata T, Furukawa T, Sunamura M, et al. RNA interference targeting aurora kinase a suppresses tumour growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005;65:2899-905.
28. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003;3:51-62.
29. Yang H, He L, Kruk P, Nicosia SV, Cheng JQ. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 2006;119:2304-12.
30. Andrews PD. Aurora kinases: shining lights on the therapeutic horizon? Oncogene 2005;24:5005-15.
31. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927-36.
32. Warner SL, Bearss DJ, Han H, Von Hoff DD. Targeting Aurora-2 kinase in cancer. Mol Cancer Ther 2003;2:589-95.
33. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumour growth in vivo. Nat Med 2004;10:262-7.
34. Lee EC, Frolov A, Li R, Ayala G, Greenberg NM. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 2006;66:4996-5002.
35. Hauf S, Cole RW, LaTerra S, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003;161:281-94.
36. Jung FH, Pasquet G, Lambert-van der Brempt C, et al. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem 2006;49:955-70.
37. Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res 2006;12:6869-75.
38. Fu S, Hu W, Kavanagh JJ, Bast RC, Jr. Targeting Aurora kinases in ovarian cancer. Expert Opin Ther Targets 2006;10:77-85.
39. Sobin LH, Wittekind C, editors. TNM - classification of malignant tumours. UICC, 6th Edition, Wiley Liss, Inc., 2002.
40. Gerlach U, Kayser G, Walch A, et al. Centrosome-, chromosomal-passenger- and cell-cycle-associated mRNAs are differentially regulated in the development of sporadic colorectal cancer. J Pathol 2006;208:462-72.
41. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumour tissue. Am J Pathol 2001;158:419-29.
42. de Kok JB, Roelofs RW, Giesendorf BA, et al. Normalization of gene expression measurements in tumour tissues: comparison of 13 endogenous control genes. Lab Invest 2005;85:154-9.
43. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001;25:402-8.
44. Lassmann S, Weis S, Makowiec F, et al. Array CGH identifies distinct DNA copy number profiles of oncogenes and tumoursuppressorgenes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med 2007;85:289-300.
45. Ewart-Toland A, Dai Q, Gao YT, et al. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 2005;26:1368-73.
46. Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL, Li SA. Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci U S A 2004;101:18123-8.